(ARVN) Arvinas, Inc. Company Overview

What does Arvinas do?

Arvinas, Inc. is a New Haven, Connecticut biotechnology company listed on Nasdaq under ARVN. Its core technology is PROTAC targeted protein degradation: small, heterobifunctional molecules designed to bring a disease-causing protein into contact with the body’s ubiquitin-proteasome disposal machinery. Instead of merely blocking a protein’s active site, a degrader is intended to remove the protein itself. That mechanism is strategically important because it may address proteins with scaffolding functions, mutation-driven disease biology, or targets historically considered difficult to drug.

In 2026, Arvinas moved beyond the clinical-stage label. The U.S. Food and Drug Administration approved VEPPANU, or vepdegestrant, on May 1 for patients with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. The FDA approval provided clinical validation that preclinical research could not.

Which therapeutic areas define the company?

Arvinas now combines an approved-product royalty and milestone opportunity with a still research-intensive pipeline. Its official pipeline spans oncology, neuroscience, and neuromuscular disease. That breadth creates multiple shots on goal, but it also makes portfolio prioritization essential because every clinical program competes for cash, management attention, trial sites, and manufacturing capacity.

How does Arvinas make money?

Arvinas does not yet have a mature recurring-sales model. Its reported revenue is primarily collaboration accounting, license consideration, research funding, development milestones, and potential future royalties. That distinction is crucial: a large revenue quarter can reflect the timing of cost-to-cost revenue recognition or a milestone rather than prescription demand. Investors therefore need to separate accounting revenue from cash receipts and from the commercial economics retained after a partner agreement.

What changed after the VEPPANU approval?

Arvinas and Pfizer selected Rigel Pharmaceuticals for exclusive global development, manufacturing, and commercialization rights. Under the announced terms, Arvinas and Pfizer are to receive $70.0 million upfront and $15.0 million after specified transition activities, split evenly. They are also eligible for up to $320.0 million of development, regulatory, and commercial milestones and tiered royalties in the mid-teens to mid-20s, again shared evenly. Rigel is responsible for the U.S. launch and can sublicense outside the United States; it also agreed to contribute up to $40.0 million toward ongoing development activities. The Rigel transaction terms convert Arvinas’s role from prospective co-commercializer to licensor and pipeline developer.

Why is reported revenue unusually volatile?

FY2025 revenue was $262.6 million versus $263.4 million in FY2024, but its composition changed. FY2024 included substantial Novartis transaction revenue; FY2025 included a $20.0 million Novartis milestone and more Pfizer collaboration revenue after revised trial-cost estimates. Q1 2026 revenue then fell to $15.6 million from $188.8 million. A conventional revenue-growth multiple can therefore mislead until royalties or product economics become material.

Which products and pipeline programs matter most?

How should the pipeline be ranked?

VEPPANU ranks first for validation and near-term economics, but it is no longer the main internal spending engine. ARV-102 tests whether degraders can reach central nervous system targets, supported by greater than 50% LRRK2 reduction in cerebrospinal fluid across tested doses. ARV-806 targets the competitive KRAS G12D field, while ARV-393 tests whether catalytic degradation can outperform inhibition of a transcriptional regulator.

What is the portfolio’s central strategic tension?

The company must prove that VEPPANU is the first example of a repeatable discovery and development engine rather than a singular success. At the same time, it must avoid spreading resources too thinly. ARV-102, ARV-806, and ARV-393 each address distinct biology, patient populations, and competitor sets; success in one does not guarantee success in another. Portfolio value therefore depends on disciplined stop/go decisions, early biomarker evidence, partner interest, and financing runway.

What do Arvinas’s latest results show?

The most recent complete financial period available is the quarter ended March 31, 2026. The Q1 2026 results show a company with substantial liquidity, sharply reduced expenses, and a return to accounting losses after an unusually high-revenue comparison quarter.

Why did expenses fall?

R&D declined 33.6% year over year in Q1 2026. Compensation expense fell $15.6 million and external expense fell $14.2 million. Vepdegestrant spending dropped $15.2 million while ARV-806 rose $5.6 million. G&A declined 28.2%, mainly because professional fees fell $5.3 million. The changes reflect restructuring and the decision not to build a VEPPANU sales organization.

What does the cash trend imply?

The quarter used $69.2 million of operating cash and $1.3 million for property and equipment. A simple cash-burn measure is operating cash outflow plus capital expenditure, or about $70.5 million for Q1 2026. That one-quarter rate should not be mechanically annualized because milestone receipts, partner reimbursements, restructuring, and trial timing create volatility. Still, it is a useful discipline check against management’s runway statement in the Q1 2026 Form 10-Q.

Strategic turning points that shaped Arvinas

1. 2013
   The original Yale license gave Arvinas exclusive worldwide rights to specified protein-degradation intellectual property arising from Craig Crews’s research. This became the platform’s legal and scientific foundation.
2. 2015–2017
   Genentech and Pfizer research collaborations supplied non-dilutive funding and validated pharmaceutical interest before Arvinas had late-stage clinical evidence.
3. 2018
   The Nasdaq initial public offering expanded access to equity capital needed for a broad, expensive clinical pipeline.
4. 2021
   The global Pfizer collaboration for vepdegestrant brought a $650.0M upfront payment and shared development, creating the company’s largest strategic partnership.
5. 2024
   Arvinas licensed luxdegalutamide to Novartis for $150.0M upfront and substantial contingent economics, demonstrating willingness to monetize assets rather than fund every program internally.
6. 2025
   VERITAC-2 succeeded in the ESR1-mutated population but not the full intention-to-treat population. Two combination trials were removed, and workforce reductions of about 33% and then another 15% reset the cost base.
7. 2026
   Randy Teel became CEO, VEPPANU became the first FDA-approved PROTAC, and Rigel was selected to commercialize it. Arvinas emerged as a leaner platform developer with externally monetized commercial assets.

What did the 2025 reset change?

The reset narrowed the model. Arvinas abandoned plans for its own vepdegestrant sales organization, cut spending, and emphasized ARV-102, ARV-806, ARV-393, ARV-027, and selected preclinical assets. The 2025 Form 10-K reports 246 employees, including 188 in R&D and more than 167 with advanced degrees. FY2025 net restructuring charges were $3.7 million, including $15.3 million of cash severance partly offset by compensation reversals.

What gives Arvinas a competitive advantage?

Arvinas’s strongest advantage is no longer merely an early scientific lead. It translated academic intellectual property into a Phase 3 trial, an NDA, and an FDA-approved medicine. That process created know-how in degrader chemistry, E3 ligase selection, biomarkers, clinical operations, manufacturing, and regulation. Competitors can pursue the modality, but they cannot instantly reproduce the learning behind an approval.

How important is intellectual property?

Arvinas owns, co-owns, and licenses patent families covering platform constructs and individual programs. At December 31, 2025, ARV-393 patent families had expected expirations between 2042 and 2045 if granted, ARV-027 families between 2037 and 2044, and ARV-6723 families between 2044 and 2045. Vepdegestrant-related applications included composition, treatment, formulation, manufacturing, dosing, and combination claims, with some potential expirations extending into 2046. The moat is therefore layered, but not absolute: pending claims can be narrowed, invalidated, designed around, or challenged.

Which capabilities are difficult to copy?

A resource-based analysis highlights three capabilities: a validated degrader-design platform, experienced scientific talent, and a collaboration network spanning Yale, Pfizer, Novartis, Genentech, and Rigel. These resources are valuable and relatively scarce, but the advantage is only durable if clinical execution remains superior. Because Arvinas relies on contract manufacturers and partners, its edge lies more in molecule design, translational science, and portfolio judgment than in production scale or direct distribution.

Who are Arvinas’s main competitors?

Competition operates at two levels: platform specialists pursue targeted protein degradation, while each Arvinas program also competes with inhibitors, antibodies, endocrine therapies, cell therapies, and other modalities. The 2025 filing names C4 Therapeutics, Kymera, Nurix, Accutar, Cullgen, Foghorn, and Proteovant among degrader competitors, alongside large pharmaceutical companies.

Is Arvinas a market leader?

Arvinas can credibly claim modality leadership because VEPPANU is the first FDA-approved PROTAC. It cannot claim leadership in every therapeutic market it enters. Breast cancer already has established endocrine and targeted therapies; KRAS drug development is crowded; Parkinson’s disease has multiple genetically and biologically targeted approaches; lymphoma has effective combinations and rapidly evolving immunotherapies. Leadership must therefore be re-earned program by program through comparative efficacy, safety, convenience, price, and reimbursement.

How financially strong is Arvinas?

Arvinas’s balance sheet is stronger than its income statement. At March 31, 2026, current assets were $630.7 million versus $115.9 million of current liabilities, a current ratio of about 5.4 times. Long-term debt was only $0.3 million. The main financial risk is sustained R&D spending before milestones, royalties, partnerships, or financing replenish cash.

How did Arvinas allocate capital in 2025?

FY2025 operating cash use was $261.0 million. The company also repurchased 10.0 million shares for $91.9 million, reducing year-end shares outstanding to 63.5 million from 68.8 million a year earlier despite equity-plan issuance and warrant exercises. R&D expense was $285.2 million, G&A was $95.9 million, and net loss was $80.8 million. The buyback was material relative to cash burn and reduced dilution, but it also consumed liquidity that could otherwise fund trials.

The reported runway into the second half of 2028 gives management time to collect data from multiple programs, but runway is not the same as self-funding. A failed trial, larger pivotal study, delayed milestone, or expensive business-development transaction could shorten it. Conversely, Rigel payments, milestones, royalties, and new out-licenses could extend it.

Who owns Arvinas stock, and how is it governed?

Arvinas has one common-stock class and does not have founder super-voting control. Its investor base is institutionally influenced, while Pfizer is both a strategic shareholder and collaboration partner. The 2026 proxy statement based ownership percentages on 64,511,536 shares outstanding at March 31, 2026.

How concentrated is voting influence?

Randy Teel became president, CEO, and a director in February 2026. John Houston retired as CEO and chair but remained a director and consultant; Briggs Morrison became chair. Separating the CEO and chair roles can strengthen oversight during the portfolio transition. Equity-heavy incentives tied to scientific and operating goals align management with milestones but can also encourage catalyst-focused decisions.

What opportunities and risks could change the story?

Which opportunities have the highest strategic value?

A positive brain-penetrant degrader result could expand neuroscience partnering interest; a differentiated KRAS program could attract oncology partners; and the first approved PROTAC may improve negotiating leverage. The company’s partnership history shows a willingness to monetize programs at different stages rather than retain full ownership.

What risks are most material?

The risk structure resembles a Porter-style high-rivalry market with powerful buyers and partners. Large pharmaceutical collaborators possess capital, development infrastructure, and commercial reach; payers influence price and access; specialized scientific labor and contract manufacturing can be constrained; and substitutes are abundant. Arvinas offsets those forces with differentiated intellectual property, first-mover clinical experience, and a strong cash position, but it cannot eliminate them.

Why does Arvinas matter for valuation?

A standard DCF based on current revenue and operating margin poorly represents Arvinas because collaboration revenue is lumpy and most value lies in uncertain future cash flows. A better framework is risk-adjusted net present value by program, plus cash and securities, minus corporate costs and obligations. Each asset requires assumptions for success probability, launch timing, eligible patients, market share, price, royalties, milestones, development costs, and patent life.

Which KPIs should researchers monitor?

• Clinical target engagement: percentage protein degradation in the relevant tissue, not only blood exposure.
• Clinical efficacy: response rate, progression-free survival, functional measures, and duration of benefit.
• Safety and tolerability: serious events, discontinuations, liver signals, dose intensity, and delayed effects.
• Cash runway: cash plus securities divided by a normalized forward burn estimate, adjusted for milestone timing.
• Partner economics: cash received, deferred revenue recognition, milestones, royalties, and cost-sharing obligations.
• Portfolio productivity: programs entering the clinic, time to proof-of-concept, and capital spent per decisive data set.
• Share count: dilution from equity compensation or financing versus repurchases and milestone-funded operations.

The valuation debate is therefore a debate about probabilities, not a simple earnings multiple. Researchers should use the official financials and filings archive to update each probability and cash-flow assumption as new trial data, commercial disclosures, and partner payments arrive.

What is the key takeaway from Arvinas analysis?

Arvinas matters because it converted targeted protein degradation from a compelling scientific concept into an FDA-approved therapy. That achievement supports the credibility of its platform, strengthens its partnership position, and gives its pipeline more weight than a collection of unvalidated early-stage assets. The company also has a strong, low-debt balance sheet and has reduced its expense base after deciding not to build a commercial organization around VEPPANU.

The central weakness is that repeatability remains unproven. VEPPANU does not guarantee that ARV-102 will deliver neurological benefit, ARV-806 will outperform other KRAS approaches, or ARV-393 will establish a differentiated lymphoma profile. Revenue is episodic, partners control important decisions, and the business consumes cash. The 2025 restructuring improved efficiency but leaves an execution question: can a smaller organization advance several distinct programs without losing speed or depth?